Technology Bundle ID: TAB-2694

Novel Epitopes of Bacillus anthracis Lethal Factor for Development of Diagnostics and Therapeutics

Request More Info
Licensing Contact:
Primary Inventors: 
Anne Boyer (CDC), Jason Goldstein (CDC)
Co-Inventors: 
Conrad Quinn (CDC), Dennis Bagarozzi (CDC)
Development Stage: 
Pre-Clinical (in vitro)
Development Status: 
  • Early-stage
  • In vitro data available
Institute or Center: 
CDC

CDC researchers have characterized epitopes of Bacillus anthracis Lethal Factor (LF), a critical component of the B. anthracis lethal toxin. These epitopes may allow for development of therapeutics for the treatment or prevention of B. anthracis infection. They may also allow screening for B. anthracis LF in a sample and development of a peptide anthrax vaccine.

Applications:
  • Diagnostic tests assessing active Lethal Factor in a sample
  • Anthrax neutralizing therapeutics and vaccines for B. anthracis
  • Biodefense, biosecurity
Advantages:
  • Potentially faster, lower-input assay compared to current Edema Factor detection methods
  • Easily adaptable for high-throughput screening of numerous specimens

Patents

PCT Application PCT/US2013/059179
Filed on 2013-09-11
US Application 14/427,329
Filed on 2015-03-11
US Application 61/699,738
Filed on 2012-09-11

Publications

Boyer AE, et al.
PMID 17929949

Updated

Dec 23, 2013

Data Source: 
tts